Riding Outsourcing Wave, Ex-Teva Exec To Head CRO Albany Molecular
This article was originally published in The Pink Sheet Daily
Executive Summary
A year after leaving Teva as a full-time employee, Bill Marth will succeed Albany Molecular Research’s founding CEO at the beginning of 2014. The company believes an increase in capital availability and a return to R&D spending will fuel a trend toward outsourced pharma services.
You may also be interested in...
CROs And Biopharma Weigh The Balance Of Risk And Responsibility
Biopharmaceutical companies have been outsourcing R&D activity to CROs for a while, but neither they nor CROs have sorted out which side should bear the burden of what kind of risk and how to best structure operations.
Overhauling Teva: Conversations With Jeremy Levin And Michael Hayden
Teva CEO Jeremy Levin and the CSO he hired, Michael Hayden, want to re-focus the company on innovative R&D and selective generics opportunities, and that means an overhaul of the R&D organization and new priorities for business development. Levin and Hayden spoke to IN VIVO about their goals and shaping these activities following a widely anticipated investor briefing on December 11 in New York City.
Craig Venter Wants To Extend Your Life (And Own Your Data)
The onetime Celera CEO says his new attempt to centralize biological information into a massive database could lead to breakthroughs that extend the human life span. Behind that bold goal is a more mundane data-licensing strategy that, although not splashy, could still improve medicine.